Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Medtronic
Boehringer Ingelheim
Colorcon
AstraZeneca

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ipatasertib

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Ipatasertib: Patents, clinical trial progress, indications

Ipatasertib is an investigational drug.

There have been 19 clinical trials for Ipatasertib. The most recent clinical trial was a Phase 1 trial, which was initiated on June 20th 2017.

The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Medical Research Council.

There are twenty-four US patents protecting this investigational drug and three hundred and seventy-eight international patents.

Recent Clinical Trials for Ipatasertib
TitleSponsorPhase
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast CancerHoffmann-La RochePhase 3
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)Genentech, Inc.Phase 1
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)Massachusetts General HospitalPhase 1

See all Ipatasertib clinical trials

Clinical Trial Summary for Ipatasertib

Top disease conditions for Ipatasertib
Top clinical trial sponsors for Ipatasertib

See all Ipatasertib clinical trials

US Patents for Ipatasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ipatasertib   See Pricing Polymeric nanoparticles and methods of making and using same Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY)   See Pricing
Ipatasertib   See Pricing Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use GENENTECH, INC. (South San Francisco, CA)   See Pricing
Ipatasertib   See Pricing Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors Array BioPharma Inc. (Boulder, CO) Covenentech, Inc. (South San Francisco, CA)   See Pricing
Ipatasertib   See Pricing Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors Array Biopharma, Inc. (Boulder, CO) Genentech, Inc. (South San Francisco, CA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ipatasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Ipatasertib European Patent Office 3119395 2034-03-17   See Pricing
Ipatasertib World Intellectual Property Organization (WIPO) 2015142605 2034-03-17   See Pricing
Ipatasertib Australia 2012236135 2031-04-01   See Pricing
Ipatasertib Australia 2012236138 2031-04-01   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
McKinsey
Colorcon
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.